FDA authorizes first standalone robotic blood-draw device

The Food and Drug Administration authorized the first standalone robotic device capable of drawing blood from a patient’s arm without hands-on operator intervention on August 19.

Vitestro’s Aletta received marketing authorization through the De Novo pathway, which FDA uses for novel devices presenting low to moderate risk when no legally marketed predicate exists. The decision permits its use with adults in outpatient settings and establishes a regulatory category and special controls that future devices of the same type may be able to follow.

The authorization matters because venous blood collection underpins routine screening, disease monitoring and many diagnostic decisions. Automating collection could eventually help laboratories manage staffing constraints and standardize parts of the preanalytical process. Those operational benefits have not yet been demonstrated in comparative health-system studies.

What the device does

A phlebotomy-trained supervisor initiates each session and remains available to intervene. FDA says one supervisor may oversee as many as three devices simultaneously.

After guiding the patient’s arm into position, Aletta uses near-infrared imaging, ultrasound and Doppler ultrasound to identify a suitable vein and distinguish it from an artery. It does not attempt venipuncture when it cannot identify an appropriate vein.

When the device proceeds, it applies a tourniquet, disinfects the skin, inserts the needle, changes collection tubes, disposes of the needle and applies a bandage. The supervisor checks that tubes were collected in the correct order and adequately filled. Excessive patient movement causes the needle to detach and the procedure to stop, while other sensors can pause operation and alert the supervisor.

Authorization therefore does not make blood collection an unsupervised procedure or eliminate responsibility for specimen verification and patient support.

What the clinical evidence found

A peer-reviewed multicenter study published in *Clinical Chemistry* evaluated an investigational version of the system in outpatient phlebotomy departments in the Netherlands. The manufacturer funded the study, and several authors were employees or equity holders.

An analytical-equivalence cohort enrolled 153 participants. Paired samples from 119 participants were available for comparison after exclusions. Investigators reported no statistically or clinically significant differences between robotic and manually collected samples for the selected laboratory measurements, which included clotting times, platelet count and several enzymes. The study did not assess every commonly ordered analyte.

A routine-use cohort enrolled 1,633 patients. Among patients for whom the device identified a suitable vein, first-stick success was 94.5%, including 92.7% among participants reporting difficult venous access, 97.4% among those with obesity and 93.4% among adults aged 65 or older.

That conditional result requires context. The device found no suitable vein in 6% of screened patients. When those patients were included, overall collection success was 88.5%, or 1,543 of 1,743 attempts. Mild adverse events occurred after 0.6% of robotic venipunctures; no moderate or serious adverse events were reported in the paper.

Among 939 participants completing a postprocedure survey, 90% rated the pain as similar to or less than that of prior manual blood draws. Eighty-two percent preferred the robot, strongly preferred it or expressed no preference for a future draw.

What remains uncertain

The routine-use portion was single-arm, so it did not directly randomize patients between robotic and manual phlebotomy. Comparisons with human first-stick performance relied on published literature that may involve different populations and clinical conditions. Patient-experience data were collected from only a subset, and the analytical study evaluated a limited test panel.

The published trial also cannot establish that allowing one supervisor to monitor three devices will shorten waits, reduce costs, expand access or improve laboratory staffing in US practice. Those claims require prospective workflow and implementation studies.

FDA’s decision supports the device’s safety and effectiveness for its authorized use. Its practical significance is narrower: supervised autonomous blood collection can now enter the US market under defined regulatory controls, while its real-world effects on diagnostic access, specimen quality and the phlebotomy workforce remain to be measured.